Glembatumumab

CAS No. 1020264-78-1

Glembatumumab( —— )

Catalog No. M36895 CAS No. 1020264-78-1

Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 559 In Stock
10MG 900 In Stock
25MG 1311 In Stock
50MG 1758 In Stock
100MG 2372 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Glembatumumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma.
  • Description
    Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ADC Antibody
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1020264-78-1
  • Formula Weight
    Approximately 145.56 kDa
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Naumovski L, et al. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther. 2010 Apr;12(2):248-57.?
molnova catalog
related products
  • RGDV

    RGDV is a platelet aggregation inhibitor. RGDV inhibits platelet-dependent thrombus formation. RGDV is used for tumor recognition via the targeting effect.

  • Yadanzigan

    Yadanzigan (YDZG) is an anti-inflammatory agent and a NLRP3 inhibitor. Yadanzigan specifically inhibits NLRP3 activation via inhibiting NF-κB pathway and Reactive Oxygen Species production. Yadanzigan also moderates LPS -induced acute lung injury (ALI) in mice.

  • Meclocycline sulfosa...

    Meclocycline (INN) is a tetracycline antibiotic. It is used topically (i.e. for skin infections) as it is totally insoluble in water and may cause liver and kidney damage if given systemically.